Tesaro Shares Tumble After Disappointing Data Results

By: Benzinga
Shares of Tesaro (NASDAQ: TSRO ) dropped as much as 32.19% to $28.52 following the announcement that data from two trials showed that rolapitant for chemotherapy induced nausea and vomiting (CINV) missed secondary endpoints. BMO Capital Markets analyst Jim Birchenough reported that investors had expected Tesaro's rolapitant to differentiate
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.